Skip to main content

MoneyWorks4Me

Cadila Healthcare informs about press release

13 Dec 2021 Evaluate

Cadila Healthcare has informed that it enclosed a copy of press release dated December 13, 2021 titled ‘Zydus to begin Phase II (a) clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Cryopyrin-Associated Periodic Syndrome (CAPS) in Australia’.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1905.00
Dr. Reddys Labs. 1385.00
Cipla 1406.00
Lupin 2012.00
Zydus Lifesciences 1213.05
View more..